Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Conditions
Postoperative Delirium, Postoperative Cognitive Dysfunction
Interventions
CN-105, Placebo
Drug
Lead sponsor
Miles Berger, MD PhD
Other
Eligibility
60 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

NCT06899802
Conditions
Encephalitis
Interventions
MVA-BN-WEV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Sacramento, California • Lilburn, Georgia • Lenexa, Kansas + 6 more
Conditions
Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration, Inflammation, Brain
Interventions
Lenalidomide 10 mg, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Conditions
Systemic Lupus Erythematosus
Interventions
Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Completed No phase listed Observational Results available

Evaluation of Moderate to Severe Influenza Outcomes in Children

NCT02979626
Conditions
Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection, Myositis Viral, Fever
Interventions
Respiratory nasal swab
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 8 Years
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado • Broomfield, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of West Nile Virus Vaccine

NCT00300417
Conditions
West Nile Fever
Interventions
VRC-WNVDNA020-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Infectious Metabolic Encephalopathy, Ischemic Stroke, Seizure, Viral Encephalitis, Small and Large Vessel
Interventions
keypresses
Behavioral
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
Interventions
Placebo, EG-501
Drug
Lead sponsor
Evergreen Therapeutics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Brain Inflammation in Major Depressive Disorder Background

NCT01851356
Conditions
Major Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Japanese Encephalitis
Interventions
Blood draw, IC51 has given in the parent study IC51-322
Procedure · Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
9 Months to 20 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
Interventions
89 Zr-Df-crefmirlimab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

NCT00314145
Conditions
Japanese Encephalitis
Interventions
ChimeriVax™-JE, JE-VAX®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Chicago, Illinois • Shawnee Mission, Kansas • Missoula, Montana + 2 more
Conditions
HSV Encephalitis
Interventions
To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Clindamycin
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Eastern Equine Encephalitis
Interventions
Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Fort Deterick, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity

NCT04116229
Conditions
Obesity
Interventions
Oral glucose tolerance test, Cognitive testing, Magnetic resonance imaging
Procedure · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
Interventions
Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 71 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Seattle, Washington
Completed No phase listed Observational Accepts healthy volunteers

The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)

NCT03710278
Conditions
Meningitis, Encephalitis, Guillain-Barré, Subarachnoid Hemorrhage, Intracranial Neoplasm, Intracranial CNS Disorder
Interventions
LPat Device
Device
Lead sponsor
Spartanburg Regional Healthcare System
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Spartanburg, South Carolina
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Interferon alfa-2b, Zidovudine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Conditions
Autoimmune Encephalitis (AE)
Interventions
Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Tucson, Arizona • Sherman, Texas
Suspended Phase 1 Interventional Accepts healthy volunteers

Measuring Brain Inflammation in Autism

NCT03117530
Conditions
Autism Spectrum Disorder
Interventions
Minocycline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational

A Case Report of NMDAR Encephalopathy

NCT06915103
Conditions
Anti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes
Interventions
Magnetic Resonance Imaging (MRI), Salpingo-oophorectomy
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
34 Years to 34 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Myasthenia Gravis, Guillain-Barre Syndrome, Multiple Sclerosis, Seizures, Parkinsonism, Meningitis, Encephalitis, Headache, Vestibular Disorder, Spondylosis, Normal Pressure Hydrocephalus
Interventions
Current standard discharge educational intervention, Personalized discharge educational intervention
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire